Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study
出版年份 2017 全文链接
标题
Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study
作者
关键词
Metastatic prostate cancer, Castration-resistant prostate cancer, Systemic agents, Adjuvant therapy, SEER Program, Urology
出版物
INTERNATIONAL UROLOGY AND NEPHROLOGY
Volume 50, Issue 1, Pages 71-78
出版商
Springer Nature
发表日期
2017-11-11
DOI
10.1007/s11255-017-1744-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era
- (2017) Michele Marchioni et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries
- (2016) et al. CANCER
- Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992–2013
- (2016) Anne-Michelle Noone et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective
- (2016) Jeremy Yuen Chun Teoh et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Propensity score matching and randomization
- (2015) George Mnatzaganian et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Docetaxel with or without zoledronic acid for castration-resistant prostate cancer
- (2014) Yue Pan et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- The Diffusion of Docetaxel in Patients With Metastatic Prostate Cancer
- (2014) Joseph M. Unger et al. JNCI-Journal of the National Cancer Institute
- No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period
- (2013) Jennifer N. Wu et al. CANCER
- Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old
- (2012) Hideaki Miyake et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
- (2012) Catherine M. Tangen et al. JOURNAL OF UROLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now